Gosset Ownership
Private
Employees
~315
Therapeutic Areas
Stage
Commercial
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
siParadigm General Information
siParadigm provides comprehensive molecular and genomic profiling for solid tumors and hematologic malignancies using advanced diagnostic technologies. Their test menu covers actionable aberrations including SNVs, InDels, CNVs, gene fusions, splice variants as well as tumor mutation burden and microsatellite instability. They offer both tissue-based and liquid biopsy testing with rapid turnaround times[1][4].
Contact Information
Primary Industry
Molecular Diagnostics
Corporate Office
Pine Brook, New Jersey
United States
United States
Drug Pipeline
No pipeline data available
Key Partnerships
Acquired the clinical laboratory business of Cancer Genetics Inc. in July 2019[5].
siParadigm Funding
No funding data available
To view siParadigm's complete valuation and funding history, request access »